Exploring anti-TGF-beta beta therapies in cancer and fibrosis

Author(s):
Hawinkels, L.J.A.C.; Dijke, P. ten (0000-0002-2875-4723)
Published
2011
Publication type
Article / Letter to editor

Abstract

On the basis of these observations, small molecule inhibitors of the TGF-beta beta receptor kinases, neutralizing antibodies that interfere with ligand--receptor interactions, antisense oligonucleotides reducing TGF-beta beta expression, and soluble receptor ectodomains that sequester TGF-beta beta have been developed to intervene with excessive TGF-beta beta signaling activity in the aforementioned disorders. Here, we review the current state of anti-TGF-beta beta therapy in clinical trials.

TGF-beta Smad ALK5 fibrosis cancer clinical trial growth-factor-beta cell lung-cancer transforming growth-factor-beta-1 level advanced gastric-carcinoma factor (tgf)-beta receptor breast-cancer systemic-sclerosis tumor-growth colorectal-cancer ii receptor
Date issued
2011-08-31
Language
English
Is part of
Growth Factors (2011), Vol. 29, no. 4, p. 140-152
hdl
1887/108639
doi
10.3109/08977194.2011.595411